Filing Flows › Vivos Therapeutics (VVOS) › Q4 2024
Vivos Therapeutics (VVOS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Vivos Therapeutics (VVOS) reported revenue of $3.7M for the fourth quarter 2024 (Q4 2024), +14% from a year earlier and -4% from the quarter before. Operating margin was -75.9%, net loss $2.8M (76.4% of revenue).
Vivos Therapeutics, Q4 2024: revenue $3.7M (+14% year over year), operating margin -75.9%, net loss $2.8M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | -4% | +14% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$2.9M | — | — |
What changed
Revenue was $3.7M in Q4 2024, up 14% year over year and down 4% from the previous quarter. Sponsorship Seminar Other was the largest line at 35% of revenue.
Gross margin was 56.7%, down 7.6 points from a year earlier. Operating costs exceeded revenue by $2.8M, an operating margin of -75.9%. Operating expenses fell 21% while revenue rose 14%. The quarter ended with a net loss of $2.8M, wider than the previous quarter's $2.6M loss.
Operating cash flow was −$2.9M. Non-cash charges added back $144K of depreciation and amortization and $57K of share-based compensation. Working capital and other items used $314K. Capital expenditures of $165K exceeded it, leaving free cash flow of −$3.1M.
Questions
What was Vivos Therapeutics' revenue in the fourth quarter 2024?
Vivos Therapeutics (VVOS) reported revenue of $3.7M for the fourth quarter 2024 (Q4 2024), +14% from a year earlier and -4% from the quarter before.
Was Vivos Therapeutics profitable in the fourth quarter 2024?
Operating loss was $2.8M (-75.9% of revenue) and net loss $2.8M.
Source: Vivos Therapeutics 10-K on SEC EDGAR.